Every material Form 8-K Rani Therapeutics Holdings, Inc. has filed with the SEC since June 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Rani Therapeutics reported second-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, and a net loss of $8.4 million, down from $11.2 million. Cash and marketable securities rose to $53.4 million, which the company says will fund operations at least through 2027, though the net loss attributable to Rani shareholders increased to $7.4 million from $6.7 million.
Q2 2026 contract revenue was $1.7 million, compared with no contract revenue in Q2 2025, primarily from the Chugai collaboration.
Net loss per Class A share attributable to Rani was $(0.04) for Q2 2026, compared with $(0.18) for Q2 2025.
Cash, cash equivalents and marketable securities totaled $53.4 million at June 30, 2026, up from $43.4 million at March 31, 2026, after a $20.0 million registered direct offering in May 2026.
Rani Therapeutics Holdings appointed Michelle Gilson to its board of directors effective August 1, 2026, and named her chair of the Audit Committee. Gilson previously served as chief financial officer of Arcellx, Inc. until its acquisition by Gilead Sciences in April 2026, and the filing describes no change to the company's financial results or guidance.
Michelle Gilson appointed to the board on August 1, 2026, serving until the next annual meeting or until a successor is appointed
Gilson also appointed chair of the Audit Committee
Gilson was CFO of Arcellx, Inc. from May 2022 until Gilead Sciences acquired it in April 2026
Company will enter into its standard indemnification agreement with Gilson
Rani Therapeutics appointed Nicholas M. Maestas as Chief Financial Officer, succeeding Svai Sanford, who had previously announced he would step down once a successor was named. The company also approved a 2026 Equity Inducement Plan reserving 5,500,000 Class A shares for new-hire awards, which does not require stockholder approval.
Maestas, age 46, was CFO and Head of Corporate Strategy at Tempest Therapeutics from January 2025 until June 2026.
Offer letter dated June 24, 2026 sets an annual base salary of $500,000 and a target bonus of 75% of base salary.
Maestas will receive a non-qualified option to purchase 2,000,000 Class A shares, vesting over four years.
The Board approved the Inducement Plan on June 28, 2026, reserving 5,500,000 shares.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Rani Therapeutics Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →